快速通道指定-话题@MedSci

#快速通道指定#

29篇内容 | 1648人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1449908, encodeId=690314499087d, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定, objectType=article, longId=203551, objectId=920d203551ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920d203551ad, replyNumber=0, likeNumber=78, createdTime=2020-11-21, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920d203551ad, moduleTitle=BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920d203551ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449907, encodeId=e7df144990ed2, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=95, createdTime=2020-10-24, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449906, encodeId=604414499065b, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定, objectType=article, longId=199754, objectId=3106199e5420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3106199e5420, replyNumber=0, likeNumber=75, createdTime=2020-08-22, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3106199e5420, moduleTitle=同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3106199e5420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449905, encodeId=79361449905bc, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定, objectType=article, longId=197673, objectId=890919e6737a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890919e6737a, replyNumber=0, likeNumber=67, createdTime=2020-07-19, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890919e6737a, moduleTitle=非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890919e6737a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449904, encodeId=d55d1449904b6, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, objectType=article, longId=196066, objectId=8dab1960666a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dab1960666a, replyNumber=0, likeNumber=77, createdTime=2020-06-19, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dab1960666a, moduleTitle=FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dab1960666a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449903, encodeId=9f941449903bd, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=Orphazyme的热休克蛋白疗法Arimoclomol治疗肌萎缩性侧索硬化症，获得美国快速通道指定, objectType=article, longId=194612, objectId=340c19461254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=340c19461254, replyNumber=0, likeNumber=69, createdTime=2020-05-24, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=340c19461254, moduleTitle=Orphazyme的热休克蛋白疗法Arimoclomol治疗肌萎缩性侧索硬化症，获得美国快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=340c19461254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449902, encodeId=e55b144990252, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定, objectType=article, longId=194118, objectId=cc4519411845, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc4519411845, replyNumber=0, likeNumber=69, createdTime=2020-05-15, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc4519411845, moduleTitle=上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc4519411845)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449901, encodeId=85f514499011a, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, objectType=article, longId=193386, objectId=63df19338615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df19338615, replyNumber=0, likeNumber=81, createdTime=2020-05-04, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df19338615, moduleTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df19338615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449900, encodeId=06e21449900b8, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, objectType=article, longId=192487, objectId=54e819248eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54e819248eed, replyNumber=0, likeNumber=60, createdTime=2020-04-20, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54e819248eed, moduleTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54e819248eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449899, encodeId=77ec144989937, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤, objectType=article, longId=192484, objectId=fb0c19248469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb0c19248469, replyNumber=0, likeNumber=68, createdTime=2020-04-20, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb0c19248469, moduleTitle=和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb0c19248469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449898, encodeId=574d14498986f, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, objectType=article, longId=192376, objectId=8eeb1923e6a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8eeb1923e6a6, replyNumber=0, likeNumber=57, createdTime=2020-04-17, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8eeb1923e6a6, moduleTitle=Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8eeb1923e6a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449897, encodeId=c0fa144989e5d, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=非阿片类镇痛药EC5026治疗神经性疼痛：获得FDA授予快速通道指定, objectType=article, longId=192008, objectId=3c4019200808, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c4019200808, replyNumber=0, likeNumber=70, createdTime=2020-04-12, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c4019200808, moduleTitle=非阿片类镇痛药EC5026治疗神经性疼痛：获得FDA授予快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c4019200808)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449896, encodeId=d89e1449896e1, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, objectType=article, longId=191734, objectId=89b6191e3439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89b6191e3439, replyNumber=0, likeNumber=82, createdTime=2020-04-10, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89b6191e3439, moduleTitle=FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89b6191e3439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449895, encodeId=9218144989589, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=Blaze Bioscience的光学成像剂BLZ-100用于"点亮"儿童中枢神经系统肿瘤，获FDA授予快速通道指定, objectType=article, longId=191725, objectId=4cf9191e258a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cf9191e258a, replyNumber=0, likeNumber=0, createdTime=2020-04-10, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cf9191e258a, moduleTitle=Blaze Bioscience的光学成像剂BLZ-100用于"点亮"儿童中枢神经系统肿瘤，获FDA授予快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cf9191e258a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449894, encodeId=787d1449894cf, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=191720, objectId=0445191e204e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0445191e204e, replyNumber=0, likeNumber=74, createdTime=2020-04-10, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0445191e204e, moduleTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0445191e204e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449893, encodeId=2e66144989385, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=190021, objectId=dadc19002166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadc19002166, replyNumber=0, likeNumber=74, createdTime=2020-03-16, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadc19002166, moduleTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadc19002166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449892, encodeId=4e8c1449892c9, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=Daré Bioscience的克林霉素水凝胶DARE-BV1获得FDA快速通道指定，用于治疗细菌性阴道病, objectType=article, longId=189906, objectId=d87818990695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d87818990695, replyNumber=0, likeNumber=92, createdTime=2020-03-14, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d87818990695, moduleTitle=Daré Bioscience的克林霉素水凝胶DARE-BV1获得FDA快速通道指定，用于治疗细菌性阴道病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d87818990695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449891, encodeId=397c1449891a6, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症，获得美国FDA的快速通道指定, objectType=article, longId=189522, objectId=bca518952213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bca518952213, replyNumber=0, likeNumber=86, createdTime=2020-03-08, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bca518952213, moduleTitle=EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症，获得美国FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bca518952213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449890, encodeId=fdbc144989025, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=Pulmatrix的吸入式抗真菌药Pulmazole获得FDA的快速通道指定，用于治疗哮喘患者的过敏性支气管肺曲霉病, objectType=article, longId=187170, objectId=62cd18e17067, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62cd18e17067, replyNumber=0, likeNumber=64, createdTime=2020-02-03, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62cd18e17067, moduleTitle=Pulmatrix的吸入式抗真菌药Pulmazole获得FDA的快速通道指定，用于治疗哮喘患者的过敏性支气管肺曲霉病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62cd18e17067)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1449889, encodeId=e96a1449889b7, content=<a href='/topic/show?id=775e52084ac' target=_blank style='color:#2F92EE;'>#快速通道指定#</a>, objectTitle=FDA授予β3-肾上腺素能受体拮抗剂APD418用于代偿性心力衰竭治疗的快速通道指定, objectType=article, longId=186459, objectId=09c218645948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09c218645948, replyNumber=0, likeNumber=87, createdTime=2020-01-19, rootId=0, userName=qidongfanjian, userId=b88a5514460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09c218645948, moduleTitle=FDA授予β3-肾上腺素能受体拮抗剂APD418用于代偿性心力衰竭治疗的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09c218645948)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

快速通道指定

2020-05-29

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定

2020-11-21

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2020-10-24

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定

2020-08-22

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

非酒精性脂肪性肝炎新药HM15211，获得FDA快速通道指定

2020-07-19

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

FDA授予伊立替康脂质体（ONIVYDE）快速通道指定，用于转移性胰腺癌的一线联合治疗

2020-06-19

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

Orphazyme的热休克蛋白疗法Arimoclomol治疗肌萎缩性侧索硬化症，获得美国快速通道指定

2020-05-24

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

上周获批II期临床后，Moderna新冠病毒mRNA疫苗又获得FDA授予的快速通道指定

2020-05-15

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验

2020-05-04

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定

2020-04-20

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤

2020-04-20

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

Alnylam的RNAi疗法Vutrisiran获得FDA快速通道指定，治疗hATTR淀粉样变性

2020-04-17

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

非阿片类镇痛药EC5026治疗神经性疼痛：获得FDA授予快速通道指定

2020-04-12

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

FDA授予ADC药物sacituzumab govitecan快速通道指定，用于治疗转移性尿路上皮癌

2020-04-10

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

Blaze Bioscience的光学成像剂BLZ-100用于"点亮"儿童中枢神经系统肿瘤，获FDA授予快速通道指定

2020-04-10

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-04-10

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-03-16

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

Daré Bioscience的克林霉素水凝胶DARE-BV1获得FDA快速通道指定，用于治疗细菌性阴道病

2020-03-14

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症，获得美国FDA的快速通道指定

2020-03-08

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

Pulmatrix的吸入式抗真菌药Pulmazole获得FDA的快速通道指定，用于治疗哮喘患者的过敏性支气管肺曲霉病

2020-02-03

qidongfanjian (审核中...)

前往app查看评论内容

#快速通道指定#

FDA授予β3-肾上腺素能受体拮抗剂APD418用于代偿性心力衰竭治疗的快速通道指定

2020-01-19

科室
- - 订阅+
  - 更多科室
工具
服务